New surveillance strategy aims to catch residual cancer early in High-Risk nasopharyngeal carcinoma

NCT ID NCT07692906

Not yet recruiting Disease control Sponsor: Xuelei Ma MD Source: ClinicalTrials.gov ↗

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This trial tests a follow-up strategy for people with nasopharyngeal cancer that has spread to neck lymph nodes (N3) after radiation therapy. Participants are assigned to standard follow-up or an enhanced approach that uses advanced imaging and a blood test (EBV DNA) to decide if a neck dissection is needed. The goal is to see if this tailored surveillance improves survival and reduces unnecessary surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Multimodal evaluation-guided surveillance strategy (imaging, CEUS, EBV DNA) with selective neck dissection
What this could lead to: If successful, this approach could reduce unnecessary surgeries and improve survival by catching residual cancer early in high-risk patients.
What could go wrong: This is a single-center trial with 80 participants, so results may not apply broadly. The surveillance strategy may not improve outcomes over standard follow-up.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CANCINOMA (NPC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nasopharyngeal carcinoma undifferentiated carcinoma of nasopharynx

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NASOPHARYNGEAL CANCINOMA (NPC)

More trials for these conditions

Other studies related to the condition(s) this trial covers.